• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Lannett Co Inc

    6/20/23 6:52:07 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LCI alert in real time by email
    S-8 POS 1 tm2318961d9_s8pos.htm S-8 POS

     

    As filed with the Securities and Exchange Commission on June 20, 2023

    Registration Statement No. 333-262534

    333-253361

    333-230461

    333-193509

    333-172304

    333-147410

    333-103236

    333-103235

    033-79258

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-262534

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-253361

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-230461

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-193509

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-172304

    Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-147410

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-103236

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-103235

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 033-79258

     

    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933
     

     

     

    LANNETT COMPANY, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation or organization)

      23-0787699
    (I.R.S. Employer Identification No.)
         

    1150 Northbrook Drive, Suite 155

    Trevose, PA

    (Address of Principal Executive Offices)

      19053
    (Zip Code)

     

    Lannett Company, Inc. 2022 Employee Stock Purchase Plan

    Lannett Company, Inc. 2021 Long-Term Incentive Plan

    Lannett Company, Inc. Amended and Restated 2014 Long-Term Incentive Plan

    Lannett Company, Inc. 2014 Long Term Incentive Plan

    Lannett Company, Inc. 2011 Long Term Incentive Plan

    Lannett Company, Inc. 2006 Long Term Incentive Plan

    Lannett Company, Inc. 2003 Employee Stock Purchase Plan

    Lannett Company, Inc. 2003 Stock Option Plan

    (Full title of the plan)

     

    Timothy C. Crew

    Chief Executive Officer

    Lannett Company, Inc.

    1150 Northbrook Drive, Suite 155

    Trevose, PA 19053

    (Name and address of agent for service)

     

    (215) 333-9000

    (Telephone number, including area code, of agent for service)

     

    Copies to:

    Timothy Cruickshank

    Jennifer Karinen

    Kirkland & Ellis LLP

    601 Lexington Avenue

    New York, NY

    Phone: (212) 446-4800

    Facsimile: (212) 446-4900

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company ¨
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE: TERMINATION OF REGISTRATION STATEMENT AND DEREGISTRATION OF SECURITIES

     

    These Post-Effective Amendments (these “Post-Effective Amendments”), filed by Lannett Company, Inc., a Delaware corporation (the “Company”), relate to the following Registration Statements on Form S-8 filed by the Company (each a “Registration Statement,” and collectively, the “Registration Statements”) with the U.S. Securities and Exchange Commission (the “SEC”):

     

    ·Registration Statement on Form S-8 (No. 333-262534), filed with the SEC on February 4, 2022, pertaining to the registration of 1,500,000 shares of common stock, par value $0.001 per share (“Common Stock”), in connection with the Company’s 2022 Employee Stock Purchase Plan.

     

    ·Registration Statement on Form S-8 (No. 333-253361), filed with the SEC on February 22, 2021, pertaining to the registration of 3,000,000 shares of Common Stock in connection with the Company’s 2021 Long-Term Incentive Plan.

     

    ·Registration Statement on Form S-8 (No. 333-230461), filed with the SEC on March 22, 2019, pertaining to the registration of 2,000,000 shares of Common Stock in connection with the Company’s Amended and Restated 2014 Long-Term Incentive Plan.

     

    ·Registration Statement on Form S-8 (No. 333-193509), filed with the SEC on January 23, 2014, pertaining to the registration of 3,000,000 shares of Common Stock in connection with the Company’s 2014 Long Term Incentive Plan.

     

    ·Registration Statement on Form S-8 (No. 333-172304), filed with the SEC on February 16, 2011, pertaining to the registration of 1,500,000 shares of Common Stock in connection with the Company’s 2011 Long Term Incentive Plan.

     

    ·Registration Statement on Form S-8 (No. 333-147410), originally filed with the SEC on November 15, 2007 and amended on November 30, 2008, pertaining to the registration of 2,500,000 shares of Common Stock in connection with the Company’s 2007 Long Term Incentive Plan.

     

    ·Registration Statement on Form S-8 (No. 333-103236), filed with the SEC on February 14, 2003, pertaining to the registration of 750,000 shares of common stock, par value $0.01 per share, in connection with the Company’s 2003 Employee Stock Purchase Plan.

     

    ·Registration Statement on Form S-8 (No. 333-103235), filed with the SEC on February 14, 2003, pertaining to the registration of 750,000 shares of common stock, par value $0.01 per share, in connection with the Company’s 2003 Stock Option Plan.

     

    ·Registration Statement on Form S-8 (No. 033-79258), filed with the SEC on May 23, 1994.

     

    On June 16, 2023, the Company emerged from bankruptcy, pursuant to that certain Amended Joint Prepackaged Chapter 11 Plan of Reorganization of Lannett Company, Inc. and its Debtor Affiliates, approved and confirmed by the U.S. Bankruptcy Court for the District of Delaware on June 8, 2023. As a result of the emergence, all offers and sales of the Company’s securities pursuant to the Registration Statements have been terminated.

     

    In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that were registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all of such securities of the Company registered but unsold under the Registration Statements.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Trevose, Commonwealth of Pennsylvania, on June 20, 2023.

     

     LANNETT COMPANY, INC.
       
       
    By:/s/ Timothy C. Crew
      Name: Timothy C. Crew
      Title: Chief Executive Officer

     

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.

     

     

    Get the next $LCI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LCI

    DatePrice TargetRatingAnalyst
    8/31/2021$7.00 → $6.00Neutral
    Roth Capital
    More analyst ratings

    $LCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Lannett with a new price target

    Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $6.00 from $7.00 previously

    8/31/21 8:50:46 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital reiterated coverage on Lannett with a new price target

    Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $7.00 from $7.50 previously

    6/10/21 9:57:43 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    SEC Filings

    View All

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:08 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:20 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:14 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Chapman John C bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 13% to 174,324 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/18/22 4:09:03 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Lepore Patrick G bought $49,000 worth of shares (100,000 units at $0.49), increasing direct ownership by 21% to 587,145 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/14/22 4:16:01 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Crew Timothy C bought $7,200 worth of shares (15,000 units at $0.48), increasing direct ownership by 3% to 604,291 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/14/22 4:14:53 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT SHARES UPDATE

    Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet Strengthening, Recapitalization or Restructuring Transaction Ongoing As Company Enters Grace Period for Failure to Pay Interest on Convertible Notes TREVOSE, Pa., April 4, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) (the "Company") today shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.

    4/4/23 6:55:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

    Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

    2/1/23 4:15:00 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LEVOFLOXACIN issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug LEVOFLOXACIN (SUPPL-11) with active ingredient LEVOFLOXACIN has changed to 'Approval' on 09/20/2024. Application Category: ANDA, Application Number: 205222, Application Classification: Labeling

    9/24/24 4:39:48 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MYCOPHENOLATE MOFETIL issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug MYCOPHENOLATE MOFETIL (SUPPL-7) with active ingredient MYCOPHENOLATE MOFETIL has changed to 'Approval' on 08/13/2024. Application Category: ANDA, Application Number: 214525, Application Classification: REMS

    8/15/24 4:43:42 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (ORIG-1) with active ingredient MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE has changed to 'Approval' on 07/15/2024. Application Category: ANDA, Application Number: 209941, Application Classification:

    7/17/24 4:37:21 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    2/10/23 9:46:33 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    6/3/22 1:48:32 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    2/11/22 8:19:58 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Financials

    Live finance-specific insights

    View All

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

    Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

    2/1/23 4:15:00 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

    TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners a

    1/25/23 6:52:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care